New kidney cancer drug trial pulled before it started
NCT ID NCT06708936
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This was an early-stage study testing a new drug called KSD-201 in people with advanced clear cell kidney cancer who had already tried other treatments. The main goal was to check safety and see if the drug could shrink tumors or slow the disease. However, the study was withdrawn before any patients were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA (CCRCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430000, China
Conditions
Explore the condition pages connected to this study.